

Supplementary Table Detail characteristics of all PE cases


| case | Highest SBP<br>(mmHg) | Highest DBP<br>(mmHg) | 24h urine protein | Early onset<br>or late onset<br>PE | Mild or<br>severe PE |
|------|-----------------------|-----------------------|-------------------|------------------------------------|----------------------|
| 1    | 155                   | 100                   | 467               | late onset                         | mild                 |
| 2    | 160                   | 108                   | 1235              | late onset                         | severe               |
| 3    | 148                   | 98                    | 348               | late onset                         | mild                 |
| 4    | 164                   | 113                   | 3567              | early onset                        | severe               |
| 5    | 160                   | 115                   | 589               | late onset                         | severe               |
| 6    | 166                   | 106                   | 943               | late onset                         | severe               |
| 7    | 152                   | 102                   | 345               | late onset                         | mild                 |
| 8    | 155                   | 105                   | 668               | late onset                         | mild                 |
| 9    | 168                   | 116                   | 4455              | early onset                        | severe               |
| 10   | 149                   | 107                   | 396               | late onset                         | mild                 |

DBP, Diastolic blood pressure.

SBP, Systolic blood pressure.

PE, preeclampsia.

**Fig 6**




GAPDH-2

control

hypoxia treatment

36kDa






GAPDH-3


control

hypoxia treatment

36kDa










HIF-1a-2

control

hypoxia treatment

120kDa








HIF-1a-3

control

hypoxia treatment

120kDa





VEGF-1

control

hypoxia treatment

46kDa




VEGF-2

control

hypoxia treatment

46kDa




VEGF-3



control

hypoxia treatment

46kDa



**Fig 12**



GAPDH-3


oe-NC

oe-FtMt

sh-NC

sh-FtMt

36kDa



HIF-1a-1


oe-NC



oe-FtMt

sh-NC

sh-FtMt

120kDa





HIF-1a-2



oe-NC


oe-FtMt

sh-NC

sh-FtMt

120kDa








HIF-1a-3

oe-NC    oe-FtMt    sh-NC    sh-FtMt

120kDa





VEGF-1


oe-NC

oe-FtMt

sh-NC

sh-FtMt

46kDa



VEGF-2


oe-NC

oe-FtMt

sh-NC

sh-FtMt

46kDa



VEGF-3

oe-NC

oe-FtMt

sh-NC

sh-FtMt

46kDa

